2. Search Result
Search Result
Results for "

Bromine domain

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124284
    Hexamethylene bisacetamide

    HMBA

    		 Apoptosis p38 MAPK Akt NF-κB Notch Bcl-2 Family MDM-2/p53 Epigenetic Reader Domain Neurological Disease Metabolic Disease Cancer
    Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice .
    Hexamethylene bisacetamide
  • HY-163729
    I-BET787

    		Epigenetic Reader Domain Inflammation/Immunology
    I-BET787 is a pan-BET bromine domain inhibitor with oral activity. I-BET787 shows effectiveness in a mouse model of inflammation .
    I-BET787
  • HY-117690
    dBRD9

    		PROTACs Epigenetic Reader Domain Cancer
    dBRD9,a PROTAC, can selective degrades BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole BET family .
    dBRD9
  • HY-148739
    dBRD 9-A

    		PROTACs Epigenetic Reader Domain Cancer
    dBRD 9-A is a PROTAC which can selective degrade BRD9. dBRD 9-A improves the bromine domain binding profile and reduces the binding activity of the whole BET family .
    dBRD 9-A
  • HY-161711
    CBP/p300 ligand 5

    		Ligands for Target Protein for PROTAC Cancer
    CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia .
    CBP/p300 ligand 5
  • HY-150239
    BAY-364

    BAY-299N

    		 DNA/RNA Synthesis Cancer
    BAY-364 (BAY-299N) is an inhibitor of the second bromine domain in TAF1. BAY-364 inhibits the TAF1 of Kasumi-1 cells, CD34 + cells and K562 cells with IC50 values of 1.0 µM, 10.4 µM and 10.0 µM respectively .
    BAY-364
  • HY-161483
    CBP/p300 ligand 3

    		Epigenetic Reader Domain Histone Acetyltransferase Neurological Disease Cancer
    CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). CBP and p300 are two proteins with histone acetyltransferase (HAT) activity, and CBP and p300 play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, CBP/p300 can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of CBP/p300 by binding to a specific domain of the CBP/p300 protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal CBP/p300 function .
    CBP/p300 ligand 3
  • HY-136794
    SB-284851-BT

    		p38 MAPK Epigenetic Reader Domain Inflammation/Immunology Cancer
    SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1)(IC50=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET) .
    SB-284851-BT

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: